Mandrola’s Top 4 Trials from ACC 2026

Published Date: 25 Mar 2026

Trials on Impella in high-risk PCI, percutaneous left atrial appendage closure, CTO-PCI, and spironolactone in HFpEF are Mandrola’s most anticipated at the upcoming 2026 ACC meeting in New Orleans.

Read Full News

Latest News

Age-Specific Needs in Young Women With Breast Cancer

Drs Olivia Pagani and Ann Partridge discuss how to optimize the care plan for young patients with breast cancer, focusing on age-specific concerns such as fertility and long-term survivorship.

Amantadine Awakens 94-Year-Old Woman After Stroke

A short amantadine course produced eye opening and tracking within 24 hours and a GCS of 14-15 by day 4 in a case of prolonged nontraumatic impaired consciousness.

Advances in Chronic Rhinosinusitis From ARS 2026

Advances in chronic rhinosinusitis from ARS 2026 include data on biologics vs surgery rates, AI tools in clinic, and wearable tech to document clinical efficacy, as reported by Dr Vijay Ramakrishnan.

Anticipating Key Early Breast Cancer Research at ASCO 2026

Dr Bora Lim anticipates new data on bispecific antibodies and CDK4 inhibitors, as well as crucial updates on ADCs and ctDNA-guided treatments.

May 15 2026 This Week in Cardiology

Another positive digoxin trial, another classic coronary physiology study from Imperial College London (ORBITA-FIRE), news in hypertrophic cardiomyopathy, and TAVR done in the wrong patients are the topics John Mandrola, MD, discusses in this week’s podcast.

Inside OCT and IVUS: AI’s New Edge in PCI

From automatic calcium and lipid detection to post-stent expansion checks, learn how AI helps close the gap between novice and expert and why that matters for outcomes.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Drs Olivia Pagani and Ann Partridge discuss how to optimize the care plan for young patients with breast cancer, focusing on age-specific concerns such as fertility and long-term survivorship.

A short amantadine course produced eye opening and tracking within 24 hours and a GCS of 14-15 by day 4 in a case of prolonged nontraumatic impaired consciousness.

Advances in chronic rhinosinusitis from ARS 2026 include data on biologics vs surgery rates, AI tools in clinic, and wearable tech to document clinical efficacy, as reported by Dr Vijay Ramakrishnan.

Dr Bora Lim anticipates new data on bispecific antibodies and CDK4 inhibitors, as well as crucial updates on ADCs and ctDNA-guided treatments.

Another positive digoxin trial, another classic coronary physiology study from Imperial College London (ORBITA-FIRE), news in hypertrophic cardiomyopathy, and TAVR done in the wrong patients are the topics John Mandrola, MD, discusses in this week’s podcast.

From automatic calcium and lipid detection to post-stent expansion checks, learn how AI helps close the gap between novice and expert and why that matters for outcomes.

News All Time

Reining in Overdiagnosis of Papillary Thyroid Cancer: Easier Said Than Done

Cutting ultrasound referrals for nonpalpable nodules could lead to decreases in incidence

Beware of Radiation Doses Among Heart Scanners, Study Says

Coronary CT angiography, poorer countries under scrutiny for larger doses

Study Questions Use of Prostate Cancer Hormone Therapy in Certain Cases

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients

Routine Mammograms That Also Flag CVD: Two Birds With One Stone?

AI-driven quantification of breast arterial calcification on imaging could ID higher-risk women

Tiny Blood Smidges in the Brain: Amount and Location Tied to Dementia

Neuroimaging findings believed to arise from distinct pathologies

Even Patients Are Shocked by the Prices Their Insurers Will Pay

And it costs all of us

Lead Suits Cut Physician Radiation Exposure for Interventional Cardiology Cases

Median exposure reduced to 0 versus lead apron during LAAO, with possible broader applicability

PSMA-PET Cuts Need for Biopsy in Suspected Prostate Cancer

But does it cost too much?

AI Strategy Could Eliminate Radiologist Review of Low-Risk Mammograms

Approach cut workload by 64% and increased cancer detection rate versus standard strategy

Ultrasound Treatment for Prostate Cancer Has Early Advantage Versus Prostatectomy

Better continence, erectile function, but data on oncologic outcomes still 2 years away

Deepfake X-Rays Sneak Past Radiologists and AI, Underscoring Abuse Potential

Unaware they were looking at phony images, a majority of radiologists judged fakes as real

Quiz Time: Can Radiologists Spot AI Deepfakes?

You passed medical training, now see if you can pass our weekly quiz

Low Breast Cancer Recurrence Rate With Radiotherapy Tailored to Nodal Response

Locoregional recurrence rate of 2.9% overall with no variation across node-defined risk groups

False-Negative CAC Findings That Equal Zero Cluster in Certain Groups, Study Finds

Race/ethnicity and country important to consider when interpreting coronary artery calcium score

Mammography Use Declined Among Younger Women in Recent Years

Decline follows the 2009 change to USPSTF guidelines for women ages 40 to 49

Replace Yourself With AI, CEO Katz

Let's test out this new tech where the downside is a bad spreadsheet, not a missed cancer

Recommended News For You

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

Adopted cancer cells and the effects of their presence.

Combo Therapy Boosts Early CML Response but Not Long Term

Pickleball program boosts health and wellness for cancer survivors, study finds

Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening

"We Caught It Early": Advantage or Disadvantage?

From 40 to 74, the US Preventive Services Task Force advises every two years for screening mammography.

Recommended Articles For You

Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025 

Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment 

Uncovering the Hidden Picture: Using Ultrasound to Diagnose Breast Cancer 

The Significance of APTT Blood Test Results for Detecting Coagulation Disorders 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer

1.

Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options

2.

Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment

3.

The New Era of Oncology: Key Updates and Clinical Insights

4.

HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option

5.

Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

2.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot